131-I-METAIODOBENZYLGUANIDINE (131I-MIBG) THERAPY FOR REFRACTORY NEUROBLASTOMA

131-I-间碘苄基胍 (131I-MIBG) 治疗难治性神经母细胞瘤

• 批准号: 7376528
• 负责人: GREGORY A YANIK
• 金额: $ 1.07万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376528
• 关键词: chemotherapy; neoplasm /cancer; neuroblastoma

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neuroblastomas are one of the most common solid tumors of childhood. Despite modern advances in chemotherapy and radiation therapy, the ability to cure most patients with neuroblastoma is currently < 30%. Patients who fail to respond to initial chemotherapy (called induction therapy), or those patients whose tumors relapse have even a much lower chance for cure. The cure rate for such patients is < 10%. The purpose of this protocol is to treat those patients with the greatest chance of dying from their cancer- those patients with relapsed neuroblastoma or those patients who fail induction therapy. The patients will be treated with a radio-active chemical that is called 131-I MIBG. The hope is that the MIBG will deliver radiation specifically to the tumor, thereby sparing the rest of the body the effects of the radiation.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。神经母细胞瘤是儿童最常见的实体瘤之一。尽管现代化学疗法和放射疗法取得了进步，但目前治愈大多数神经母细胞瘤患者的能力仍低于 30%。对初始化疗（称为诱导治疗）没有反应的患者，或者肿瘤复发的患者，治愈的机会甚至要低得多。此类患者的治愈率<10%。该方案的目的是治疗那些最有可能死于癌症的患者——那些患有复发性神经母细胞瘤的患者或那些诱导治疗失败的患者。这些患者将接受一种名为 131-I MIBG 的放射性化学物质治疗。希望 MIBG 能够专门针对肿瘤进行放射治疗，从而使身体的其他部位免受放射线的影响。